Bile Duct Cancer Treatment Market
Bile Duct Cancer Treatment market study with accurate historical and forecast projections, market size, market share, key industry trends, segment-wise analysis, comprehensive analysis on challenges, and opportunities for Bile Duct Cancer Treatment market players, and impact of regulations.
Global Market Study on Bile Duct Cancer (Cholangiocarcinoma) Treatment: North America & Europe to Hold over ~30% Market Share During 2017-2025
- Report code : PMRREP10094 |
- Industry : Life Sciences & Transformational Health |
- Published On : Jul-2017 |
- Pages : 215 Pages |
- Format :
Persistence Market Research forecasts the global bile duct cancer treatment market to grow from about US$ 168 Mn in 2017 to about US$ 312 Mn by 2025 end. This represents a CAGR of 8% over the forecast period 2017 – 2025. The global bile duct cancer treatment market represents absolute dollar opportunity of US$ 12.5 Mn in 2018 over 2017 and incremental opportunity of US$ 144.2 Mn between 2017 and 2025.
Rise in incidence of liver and intrahepatic bile duct cancer in North America
Cancer is the leading cause of death worldwide, and the proportion of cancer deaths around the world increased from 12% in 1990 to 15% in 2015. According to the World Health Organization (WHO), cancer accounts for 8.3 million deaths each year, with 70% new cancer cases expected to be reported over the next 20 years. Incidence of liver cancer and bile duct cancer in North America has increased dramatically in the past few years. According to the cholangiocarcinoma foundation, about 6,000 people suffer from bile duct cancer every year in the United States. In the U.S, the average age of people diagnosed with cancer is between 70 and 75.
Bile duct cancer is highest among Asians and Hispanics as compared to non-Hispanic whites and blacks. The mortality rate in men is slightly higher than women suffering from bile duct cancer. The incidence rate of cholangiocarcinoma in Canada is 0.35 per 100,000 population and the number of cases are likely to increase due to a sedentary lifestyle, exposure to chemicals, and bile duct infections. Each cancer type requires advanced treatments. An increasing prevalence of cancer and the need for combination therapies is expected to increase the demand for chemotherapy - based treatments as a first line of therapy. This is likely to provide significant opportunities for players to conduct clinical trials to establish the therapeutic efficacy and launch their products in this market.
Orphan drug designations for cholangiocarcinoma drugs in the United States boosting the market
When it was identified that adequate drugs for rare disorders were not being developed in the U.S., the Congress passed the Orphan Drug Act in 1983, to incentivize companies to develop drugs for individuals with rare and neglected diseases, such as those intended for the diagnosis, prevention, and treatment of disorders that affect fewer than 200,000 people in the U.S. In April 2017, RedHill Bio was granted the orphan drug designation to its drug candidate YELIVA (ABC294640) for the treatment of cholangiocarcinoma. In August 2015, Array BioPharma reported that FDA granted the orphan drug designation to its drug candidate, varlitinib — an oral, novel pan-HER inhibitor for the treatment of bile duct cancer. In July 2015, Delcath Systems reported that FDA granted the orphan drug designation to its drug candidate melphalan for the treatment of patients with bile duct cancer. Several drug candidates have been designated as orphan drugs to gain accelerated approval and it also allows the company to benefit from a seven year marketing exclusivity, if approved for the particular indication. The FDA undertakes an accelerated approval process to bring these therapies to the market faster and make them available for patients in need.
High cost of cancer treatment in the United States restraining the bile duct cancer treatment market
The cost of cancer treatment in the US is extremely high as compared to lower income countries. According to a study by the American Society of Clinical Oncology in Chicago, it was revealed that the cost of cancer drugs are lower in Africa and India. United States follows its own economic model for the prices of cancer drugs. In the U.S law, the importation of prescription medicines from foreign countries is forbidden. According to Canadian government's Patented Medicine Prices Review Board, the consumers in United States pay 100% more than anywhere else in the country for patented drugs. The average monthly prices for generic drugs in the Unites States is ~US$ 654 compared to US $160 in India and $125 in Africa. Chemotherapy in the United States costs ~ US$ 70K per year, while in India it costs about US$ 2500 per year. According to a study published by the Institute of Medicine, in the past 50 years from 1965 to 2013, the monthly cost of cancer drug therapy has increased almost 100 times. The regulations in the United States place a heavy burden on patients and results in the discontinuation of the treatment in 20% of the patients. Due to high costs, patients seek to undertake treatment in low income countries through medical tourism.
Global Bile Duct Cancer (Cholangiocarcinoma) Treatment Market Attractiveness Analysis by Region, 2017–2025
APAC dominated the global bile duct cancer treatment market in terms of revenue in 2016 and the trend is projected to continue throughout the forecast period. APAC is the most attractive regional market, with a market attractiveness index of 2.5 over the forecast period. Revenue from the APAC market is anticipated to exhibit a CAGR of 9% during 2017-2025 to reach US$ 146 Mn by the end of 2025. The risk of liver fluke infections in most parts of Asia Pacific is the cause of increasing incidences of bile duct cancer. The North America market is expected to be the second most lucrative market in the global bile duct cancer treatment market, with an attractiveness index of 1.0 during the forecast period. Revenue from the Europe market is anticipated to register a CAGR of 6.4% over 2017-2025 to reach US$ 34.5 Mn by the end of the forecast period.
Report Introduction
The report ‘Bile Duct Cancer (Cholangiocarcinoma) Treatment Market: Global Industry Analysis (2012-2016) and Forecast (2017-2025)’ is a comprehensive compilation on the bile duct cancer treatment market and contains exclusive information regarding the market analysis, growth and forecasts for the period 2017 to 2025. Bile ducts are a series of thin tubes that reach from the liver to the small intestine. The major function of bile ducts is to move a fluid called bile from the liver and gallbladder to the small intestine, where it helps digest the fats in food. Bile duct cancer starts when the healthy cells in the bile duct begin to grow out of control to form tumors. Cancer can develop in any part of the bile duct system and can be classified into three types based on the location -
Intrahepatic bile duct cancers: These cancers develop in the smaller bile duct branches inside the liver from the left and right hepatic branches. About 5% to 10% of bile duct cancers are intrahepatic.
Extrahepatic cholangiocarcinoma: These cancers develop in the part of the bile duct that is outside the liver. These are of two types:
- Perihilar (also called hilar) bile duct cancers: These cancers develop at the hilum, where the left and right hepatic ducts have joined and are just leaving the liver. These are also called Klatskin tumors.
- Distal bile duct cancers: These cancers are found further down the bile duct, closer to the small intestine.
Bile duct cancer is a type of biliary tract cancer, which also includes gall bladder cancer; however gall bladder cancer is not included in the scope of this report, which largely focuses on intrahepatic bile duct tumors, perihilar bile duct tumors, and distal bile duct tumors.
Report Inclusions
This report is divided into four distinct parts. The first section consists of the introduction to the bile duct cancer treatment market. The second section of the report consists of the regional bile duct cancer treatment market analysis and forecast. The third section contains the competitive landscape of the global bile duct cancer treatment market and gives a list of the important players operating in this niche market. The last section of the report consists of the global bile duct cancer treatment market analysis 2012-2016 and forecast 2017-2025 by region, by treatment type, by disease indication and by distribution channel.
In the introduction, the pertinent market numbers of the global bile duct cancer treatment market are given along with the CAGR for the forecast period 2017-2025. The introduction also contains an executive summary of this detailed report through which the report audiences can have a cursory glance at this vast market. The report also contains detailed definitions of bile duct cancer and its different types along with the definitions of the various kinds of treatments administered in cases of bile duct cancer. In addition, the introduction also lists the macroeconomic factors influencing the global bile duct cancer treatment market. An opportunity analysis of the global bile duct cancer treatment market is also presented in the introduction. Along with this, the regulatory scenarios of various regions in the global bile duct cancer treatment market are also listed. Also, a list of products that are in the pipeline for the treatment of bile duct cancer is also given in the introduction.
The second section of the report contains the regional bile duct cancer treatment market analysis and forecast. In this section, the regional drivers, restraints and trends are given so that the report audience knows what factors are aiding the growth of this market and what factors are hampering the growth of this market across the various assessed regions. Besides the drivers and restraints, the trends that are applicable in the global bile duct cancer treatment market are also discussed region-wise in this section of the report.
An important section of the report focuses on the competitive landscape of the global bile duct cancer treatment market. This part constitutes information on the key market players. This competition landscape gives a dashboard view of the key companies operating in the global bile duct cancer treatment market along with their important information and broad strategy adopted to stay as leaders in the global bile duct cancer treatment market. Each of the leading companies is also profiled individually and important information about the company such as company details, company description, product portfolio along with key developments concerning the company and strategic analysis is presented.
The last section of the report contains the global bile duct cancer treatment market analysis and forecast as well as important market metrics such as the BPS analysis, year-on-year growth rates, absolute dollar opportunity and market attractiveness analysis of the bile duct cancer treatment market.
Why should you invest in this report?
If you are ready to enter the global bile duct cancer treatment market, then this report is a comprehensive guide and will give you crystal clear insights into this vast and lucrative market. All the aspects of bile duct cancer treatment are covered in this report and information is also given on the important regions of the world where this market is likely to boom in the near future and during the forecast period of 2017-2025 so that you can plan your strategies accordingly. Besides, through this report, you can gain a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, then this report will help you gauge the strategies that your competitors have adopted to stay as leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
A tested and proven research methodology for accurate estimation of market performance
Our research methodology leverages both primary and secondary research to collect the relevant market data. We have analyzed the global bile duct cancer treatment market by considering the revenue through extensive primary research to understand the usage patterns, historic trends, problems faced by oncologists, the required treatment developments, and most preferred drugs. Key opinion leaders have been considered for primary research including experienced healthcare professionals in various healthcare facilities at a country level. These estimates have further been validated with drug manufacturers, distributors, and suppliers.
Extensive secondary research has been carried out to understand the epidemiology of bile duct cancer, treatment rate, adoption rate, regulatory scenarios, average selling price, reimbursement scenario, etc., by referring to published scientific literature from various databases such as the WHO, PubMed, Springer, and Wiley among many others. We have also analyzed various companies’ annual reports_bk_01_01_2020, investor presentations, SEC filings, 10k reports_bk_01_01_2020, and press releases to fetch substantial information about the market size, trends, opportunities, drivers, and restraints.
Market Segmentation
Treatment Type
- By Treatment Type
- Gemcitabine Combination Therapy
- 5-fluorouracil Combination Therapy
- Capecitabine Combination Therapy
- Gemcitabine Single Agent
- By Services Spending
- Radiation Therapy
- Brachytherapy Services
- External Beam Radiation Therapy (EBRT)
- Surgery
- Radiation Therapy
Disease Indication
- Intrahepatic Bile Duct Cancer
- Extrahepatic Bile Duct Cancer
- Perihilar Bile Duct Cancer
- Distal Extrahepatic Bile Duct Cancer
Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region
- North America
- Latin America
- Europe
- Asia Pacific (APAC)
- Middle East Africa (MEA)
Companies covered in Bile Duct Cancer Treatment Market Report
Company Profiles
- Pfizer, Inc.
- F. Hoffman-La Roche AG
- Bristol-Myers Squibb Company
- Teva Pharmaceuticals Industries Ltd.
- Eli Lilly and Company
- Novartis AG
- Sanofi
- Fresenius Kabi AG
- Mylan N.V.
- Kyowa Hakko Kirin Co Ltd.
- Intercept Pharmaceuticals, Inc.
- Accord Healthcare Inc.
- Delcath Systems Inc.
- Celgene Corporation
- Johnson & Johnson
- Others.
